OOIR: Observatory of International Research

Papers

(The H4-Index of Headache is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice	372
The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic‐specific estimates from government health surveys	146
Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study	77
Hypertension: A new safety risk for patients treated with erenumab	68
Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study	67
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication‐overuse headache: Subgroup analysis of PROMISE‐2	63
Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study	58
Chronic versus episodic migraine: The 15‐day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency	55
Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial	46
Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients	46
Headache attributed to idiopathic intracranial hypertension and persistent post‐idiopathic intracranial hypertension headache: A narrative review	46
Headache associated with COVID‐19: Epidemiology, characteristics, pathophysiology, and management	45
Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study	45
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study	45
Toward a better understanding of persistent headache after mild COVID‐19: Three migraine‐like yet distinct scenarios	44
Cluster headache is one of the most intensely painful human conditions: Results from the International Cluster Headache Questionnaire	42
Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients	41
Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1	40
Headache characteristics and burden from chronic migraine with medication overuse headache: Cross‐sectional observations from the Medication Overuse Treatment Strategy trial	37
Remote electrical neuromodulation for acute treatment of migraine in adolescents	36
Erenumab for headaches in idiopathic intracranial hypertension: A prospective open‐label evaluation	36
Systematic review of outcomes and endpoints in preventive migraine clinical trials	35
A link between gastrointestinal disorders and migraine: Insights into the gut–brain connection	35
Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing	35
Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data	34

Neck pain associated with migraine does not necessarily reflect cervical musculoskeletal dysfunction	33
Spontaneous spinal cerebrospinal fluid‐venous fistulas in patients with orthostatic headaches and normal conventional brain and spine imaging	33
Learning the full impact of migraine through patient voices: A qualitative study	33
Smartphone‐Delivered Progressive Muscle Relaxation for the Treatment of Migraine in Primary Care: A Randomized Controlled Trial	30
Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study	29
Trigeminal neuralgia as the sole neurological manifestation of COVID‐19: A case report	29
Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trial	29
Patient experience of telemedicine for headache care during the COVID‐19 pandemic: An American Migraine Foundation survey study	29
Systematic review of outcomes and endpoints in acute migraine clinical trials	29